

# Table of Contents

Acknowledgements . . . . .	III
Preface . . . . .	V
Introduction . . . . .	VII
Table of Contents . . . . .	IX

## Chapter 1: Calcium/Phosphorus Balance. . . . . 1

<b>Discussion of Total Serum Calcium . . . . .</b>	<b>1</b>
Parathyroid Hormone (PTH) . . . . .	2
Calcitriol (1,25 Dihydroxyvitamin D) . . . . .	2
Calcitonin . . . . .	2
Other Hormones . . . . .	3
Calcium Absorption . . . . .	3
Calcium Excretion . . . . .	6
Calcium Loss . . . . .	7
Forms of Calcium in the Blood . . . . .	7
Physiologically-Active Calcium . . . . .	7
Calcium Distribution . . . . .	8
Physiologic Roles of Calcium . . . . .	9
<b>Clinical insights into understanding elevated total serum calcium . . . . .</b>	<b>11</b>
Manifestations of Hypercalcemia . . . . .	12
Endocrine Disorders . . . . .	12
Malignancy . . . . .	13
Inflammatory Disorders . . . . .	13
Medication-Induced . . . . .	14
Miscellaneous . . . . .	14
<b>Clinical considerations for managing elevated serum calcium . . . . .</b>	<b>15</b>
Hypercalcemia . . . . .	15
Hypercalcemia with Elevated PTH . . . . .	15
Hypercalcemia without Elevated PTH . . . . .	15
Elevated Serum Calcium . . . . .	16
The Sulkowitch Urine Calcium Test . . . . .	17
Nutritional Considerations . . . . .	18
Vitamin F Complex . . . . .	19
Phosphoric Acid . . . . .	20
Avoidance Considerations . . . . .	20
Detoxification Considerations . . . . .	20
<b>Clinical insights into understanding decreased serum calcium . . . . .</b>	<b>21</b>
Decreased Calcium Entry Into Serum . . . . .	21
Increased Calcium Loss . . . . .	21
Calcium Pool Shifts . . . . .	22
Manifestations of Decreased Serum Calcium . . . . .	22
<b>Clinical considerations for managing decreased serum calcium . . . . .</b>	<b>23</b>
Nutritional Considerations . . . . .	23
Improving Calcium Absorption . . . . .	23

Calcium Excretion . . . . .	25
Calcium Choices . . . . .	26
Calcium Dosing Considerations . . . . .	30
Calcium Intake with Other Products . . . . .	30
Caution with Calcium Co-Administration . . . . .	31
Avoidance Considerations . . . . .	31
Detoxification Considerations . . . . .	32
Oxalates . . . . .	32
<b>Discussion of Serum Phosphorus . . . . .</b>	<b>34</b>
Phosphorus Absorption . . . . .	34
Phosphorus Excretion . . . . .	35
Phosphorus Shifts . . . . .	36
<b>Clinical insights into understanding elevated serum phosphorus . . . . .</b>	<b>37</b>
Phosphate Load . . . . .	37
Renal Insufficiency . . . . .	37
Increased Tubule Reabsorption . . . . .	37
Phosphate Shifts Into the Serum . . . . .	37
Manifestations of Hyperphosphatemia . . . . .	38
<b>Clinical considerations for managing elevated serum phosphorus . . . . .</b>	<b>39</b>
Nutritional Considerations . . . . .	39
Avoidance Considerations . . . . .	39
Detoxification Considerations . . . . .	39
<b>Clinical insights into understanding decreased serum phosphorus . . . . .</b>	<b>39</b>
Manifestations of Hypophosphatemia . . . . .	40
<b>Clinical considerations for managing decreased serum phosphorus . . . . .</b>	<b>41</b>
Nutritional Considerations . . . . .	41
Avoidance Considerations . . . . .	41
Detoxification Considerations . . . . .	41
<b>The Calcium/Phosphorus Ratio . . . . .</b>	<b>42</b>
<b>Clinical considerations for managing the calcium/phosphorus ratio . . . . .</b>	<b>43</b>
<b>A Brief Discussion About Prohormone/Vitamin D<sub>3</sub> . . . . .</b>	<b>45</b>
CYP27B1 (1 $\alpha$ -Hydroxylase) . . . . .	45
Mechanisms of 1,25-Dihydroxyvitamin D <sub>3</sub> (Calcitriol)	
Action . . . . .	46
Calcium Balance . . . . .	47
Bone Mineral Density . . . . .	47
Cell Differentiation . . . . .	47
Immunity and Inflammation . . . . .	47
Lung . . . . .	48
Insulin Secretion . . . . .	49
Carboxylation Co-Factor . . . . .	49
Renin Synthesis Reduction . . . . .	49
Other Activities . . . . .	49

24,25-Dihydroxyvitamin D . . . . . 49  
 Manifestations of Vitamin D Deficiency . . . . . 50  
 Risk Factors for Vitamin D Deficiency . . . . . 51  
 Assessing Vitamin D Nutritional Status . . . . . 52  
 1,25-dihydroxyvitamin D<sub>3</sub> (Calcitriol) Levels . . . . . 53  
 Vitamin D<sub>3</sub> Sources . . . . . 54  
 Vitamin D<sub>3</sub> Dosing . . . . . 57  
 Vitamin D<sub>3</sub> Toxicity . . . . . 57  
 Drug Interactions . . . . . 58  
 Vitamin D and Cancer . . . . . 58

**A Brief Discussion About Parathyroid Hormone . . . . . 59**  
 In sum, PTH leads to an increase in the Ca/P ratio.  
 As a result, more calcium is free in the tissue. . . . . 59  
 Factors Influencing PTH Release . . . . . 59  
 Hypoparathyroidism . . . . . 60  
 Hyperparathyroidism . . . . . 60  
 Parathyroid Hypertensive Factor . . . . . 62

**A Brief Clinical Discussion About Bone Mineralization . . . . . 62**  
 (1) Provide Nutrients Needed to Build Healthy Bones . . . . . 62  
 (2) Avoid Medications that Reduce BMD . . . . . 64  
 (3) Avoid Systemic Acidity . . . . . 64  
 (4) Manage Medical Conditions that Reduce BMD . . . . . 64  
 (5) Balance and Coordinate OsteoBlasts/OsteoClasts . . . . . 65  
 (6) The Wisdom of Traditional Chinese Medicine . . . . . 65

**A Brief Discussion About Magnesium . . . . . 66**  
 Serum Magnesium Testing . . . . . 67  
 Hypomagnesemia . . . . . 67  
 Magnesium Insufficiency . . . . . 67  
 Fluoride . . . . . 69  
 Vitamin B<sub>6</sub> . . . . . 69  
 Hypermagnesemia . . . . . 69  
 Oral Magnesium Repletion . . . . . 70  
 Magnesium Choices . . . . . 70  
 Transdermal Magnesium . . . . . 71

**Chapter 1 Summary . . . . . 72**

**Chapter 2: pH and Cellular Lipid Regulation . . . . . 73**

**Basic Vocabulary of Acid–Base Interpretation . . . . . 73**  
**Discussion of pH . . . . . 75**  
**Discussion of the Cell Membrane Pump, Resting Potential, and Voltage . . . . . 75**  
 Sodium–Potassium ATPase . . . . . 76  
 The Resting Membrane Potential (RMP) . . . . . 76  
**Clinical Correlation of pH . . . . . 77**  
 The Na/K ATPase Pump . . . . . 77  
 Compartmentalization . . . . . 78  
 The Interstitial Regulation Matrix . . . . . 78

**Anaerobic Versus Dyaerobic; the Key to Cellular Lipid Physiology . . . . . 79**  
 Diphasic Cycles of Cellular Metabolism . . . . . 80  
 The Revisi Method . . . . . 83

**Acidosis and Alkalosis . . . . . 83**  
**General Description . . . . . 83**

**Clinical insights into understanding tissue acidity . . . . . 85**  
**Clinical insights into understanding tissue alkalinity . . . . . 86**  
**Clinical considerations for managing acid–base imbalance 86**  
 Nutritional Considerations . . . . . 86  
 Detoxification Considerations . . . . . 89  
 Overall Approach . . . . . 89  
**Chapter 2 Summary . . . . . 90**

**Chapter 3: Carbohydrate and Glucose Metabolism . . . . . 91**

**Discussion of Blood Glucose Regulation . . . . . 92**  
 Neuroendocrine Regulation of CHO Metabolism . . . . . 92  
 Somatostatin . . . . . 92  
 Glucagon . . . . . 92  
 Growth Hormone and IGF-1 . . . . . 93  
 Cortisol . . . . . 94  
 Catecholamines . . . . . 94  
 Thyroid Hormones . . . . . 94  
 Hormone Regulation of Glucose . . . . . 95  
 Osteocalcin . . . . . 95  
 Amylin . . . . . 96  
 Glucagon-Like Peptide 1 (GLP-1) . . . . . 96  
 Insulin . . . . . 96  
 Hyperglycemia . . . . . 96  
 Advanced Glycation End-Products (AGEs) . . . . . 97  
 Polyol Production . . . . . 97  
 Protein Kinase C . . . . . 97  
 Hexosamine Production . . . . . 97  
 Reactive Oxidative Stress . . . . . 97  
 Hypoglycemia . . . . . 98  
 Hemoglobin A1c . . . . . 99  
 Fructosamine . . . . . 100  
 Oral Glucose Tolerance Testing . . . . . 100

**Discussion of Insulin . . . . . 101**  
 HyperInsulinism and Insulin Resistance . . . . . 101  
 Type 2 Diabetes (T2D) . . . . . 106

**Clinical insights into understanding blood glucose and insulin dysregulation . . . . . 108**  
 Nutritional Considerations . . . . . 108  
 Vitamins . . . . . 108  
 Minerals . . . . . 109  
 Toxin Considerations . . . . . 110  
 Infectious Considerations . . . . . 110  
 Psychoemotional Considerations . . . . . 111  
 Structural Considerations . . . . . 111

**Clinical considerations for optimizing blood glucose and insulin . . . . . 111**  
 Nutritional Considerations . . . . . 112  
 AGE Inhibitors . . . . . 113  
 Aldose Reductase Inhibitors . . . . . 114  
 Protein Kinase C Inhibitors . . . . . 114  
 Reduce Hexosamine Production . . . . . 114  
 Reduce Oxidative Stress . . . . . 114  
 Peroxisome Proliferator Activated Receptor (PPAR) Agonists . . . . . 115

Anti-Inflammatories . . . . .	116	<b>Clinical insights into understanding decreased albumin . . . . .</b>	<b>150</b>
Fat Reduction . . . . .	117	Inadequate Synthesis . . . . .	150
Phytonutrients . . . . .	117	Excessive Degradation Relative to Production. . . . .	153
Prebiotics and Resistant Starches . . . . .	122	Dilution by Excessive Intravascular Water . . . . .	153
Avoidance Considerations . . . . .	123	Losses . . . . .	153
Excess Calories . . . . .	124	Redistribution . . . . .	153
Fructose, Glucose and Amylose Intake . . . . .	126	<b>Clinical considerations for managing decreased serum</b>	
Immuno-Reactive Foods . . . . .	126	<b>albumin . . . . .</b>	<b>154</b>
Inflammation . . . . .	126	Nutritional Considerations . . . . .	154
Toxins . . . . .	127	Protein Intake . . . . .	154
Detoxification Considerations . . . . .	128	Protein Digestion and Absorption . . . . .	155
<b>Discussion of Adiposity . . . . .</b>	<b>129</b>	The Enteric Nervous System . . . . .	155
Regulation of Fat Storage . . . . .	130	The Enteric Endocrine System . . . . .	156
Regional Fat Distribution . . . . .	130	Stomach Acidity . . . . .	156
Adipocyte Differentiation . . . . .	131	Protein Digestion . . . . .	158
Adiposity . . . . .	132	Protein Absorption . . . . .	159
Leptin . . . . .	132	Intestinal Permeability . . . . .	159
Leptin Resistance . . . . .	133	Avoidance Considerations . . . . .	161
Adiponectin . . . . .	134	Food Combinations . . . . .	162
Tumor Necrosis Factor (TNF- $\alpha$ ) and Interleukin-6 . . . . .	134	<b>Discussion of Total Serum Globulins . . . . .</b>	<b>162</b>
Resistin . . . . .	135	<b>Clinical insights into understanding increased globulin</b>	
Adipsin . . . . .	135	<b>levels . . . . .</b>	<b>163</b>
Visfatin . . . . .	135	<b>Clinical considerations for managing increased serum</b>	
Acylation-Stimulating Protein (ASP) . . . . .	135	<b>globulins . . . . .</b>	<b>164</b>
<b>Clinical considerations for managing adiposity . . . . .</b>	<b>136</b>	<b>Clinical insights into understanding decreased globulins . . . . .</b>	<b>164</b>
Hormonal Balance . . . . .	136	Hypogammaglobulinemia . . . . .	164
Nutrients and Food Choices . . . . .	136	<b>Discussion of A/G (Albumin/Globulin) Ratio . . . . .</b>	<b>165</b>
Detoxification . . . . .	138	<b>Clinical insights into understanding elevated A/G ratio . . . . .</b>	<b>165</b>
<b>A Brief Discussion of Type 1 Diabetes . . . . .</b>	<b>138</b>	<b>Clinical insights into understanding reduced A/G ratio . . . . .</b>	<b>165</b>
<b>Discussion of Cellular Glucose Regulation . . . . .</b>	<b>138</b>	<b>Discussion of Total Serum Proteins . . . . .</b>	<b>165</b>
<b>Clinical considerations for managing fast cellular</b>		<b>Clinical insights into understanding elevated total serum</b>	
<b>glucose oxidation . . . . .</b>	<b>140</b>	<b>proteins . . . . .</b>	<b>165</b>
Foods Recommended for a Fast Oxidizer . . . . .	141	<b>Clinical insights into understanding decreased total</b>	
Foods Allowed In Moderation for a Fast Oxidizer . . . . .	141	<b>serum proteins . . . . .</b>	<b>166</b>
Foods to be Avoided by a Fast Oxidizer . . . . .	141	<b>Discussion of Blood Urea Nitrogen (BUN) . . . . .</b>	<b>166</b>
<b>Clinical considerations for managing slow cellular</b>		<b>Clinical insights into understanding increased BUN . . . . .</b>	<b>166</b>
<b>ketogenic oxidation . . . . .</b>	<b>141</b>	Excessive Urea Production . . . . .	167
Foods Recommended for a Slow Oxidizer . . . . .	142	Impaired Kidney Perfusion . . . . .	167
Foods Allowed in Moderation for a Slow Oxidizer . . . . .	142	Urinary Tract Obstruction . . . . .	167
Foods to Be Avoided by a Slow Oxidizer . . . . .	142	<b>Clinical considerations for managing increased BUN . . . . .</b>	<b>167</b>
<b>Chapter 3 Summary . . . . .</b>	<b>143</b>	Nutritional Considerations . . . . .	167
<b>Chapter 4: Serum Protein Metabolism . . . . .</b>	<b>145</b>	Avoidance Considerations . . . . .	168
<b>Discussion of Albumin . . . . .</b>	<b>145</b>	<b>Clinical insights into understanding decreased BUN . . . . .</b>	<b>169</b>
Binding and Transport . . . . .	146	<b>Clinical considerations for managing decreased BUN . . . . .</b>	<b>170</b>
Osmotic Pressure . . . . .	146	Nutritional Considerations . . . . .	170
Free Radical Scavenger . . . . .	147	Structural Considerations . . . . .	170
Acid Base Balance . . . . .	147	<b>Discussion of Serum Creatinine . . . . .</b>	<b>171</b>
Anticoagulant Effects . . . . .	147	<b>Clinical insights into understanding elevated serum</b>	
Vascular Permeability . . . . .	147	<b>creatinine . . . . .</b>	<b>171</b>
<b>Clinical insights into understanding increased albumin . . . . .</b>	<b>148</b>	<b>Clinical considerations for managing increased serum</b>	
<b>Clinical considerations for managing increased albumin . . . . .</b>	<b>149</b>	<b>creatinine . . . . .</b>	<b>172</b>
Nutritional Considerations . . . . .	149		

Nutritional Considerations . . . . . 172

Clinical insights into understanding decreased creatinine 172

Clinical considerations for managing reduced creatinine . 173

Discussion of BUN/Creatinine Ratio . . . . . 173

Brief discussion of increased BUN/creatinine . . . . . 173

Brief discussion of decreased BUN/creatinine ratio . . . . . 173

Discussion of Uric Acid. . . . . 173

Clinical insights into understanding increased uric acid. . 176

Clinical consideration for managing increased uric acid. . 177

    Nutritional Considerations . . . . . 177

    Avoidance Considerations . . . . . 178

Clinical insights into understanding reduced uric acid . . . 178

Clinical considerations for managing reduced uric acid levels. . . . . 179

    Nutritional Considerations . . . . . 179

    Avoidance Considerations . . . . . 179

Chapter 4 Summary . . . . . 180

**Chapter 5: Non-Specific Markers of Inflammation . . . . . 181**

    Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) . . . . . 182

Discussion of C-Reactive Protein . . . . . 185

    CRP Correlates with Atherothrombosis . . . . . 186

Clinical insights into understanding elevated CRP . . . . . 187

    Cardiovascular Disease . . . . . 188

    Cerebrovascular Disease . . . . . 188

    AutoImmunity . . . . . 189

    Adiposity . . . . . 189

    Blood Glucose Dysregulation . . . . . 189

    Cancer . . . . . 189

    Infections. . . . . 190

    Smoking. . . . . 190

    Oral Estradiol . . . . . 190

    Aging . . . . . 191

    Mood Disorders . . . . . 191

    Sleep Deprivation . . . . . 191

Clinical considerations for managing elevated CRP. . . . . 191

    Nutritional Considerations . . . . . 193

    The Anti-Inflammatory Diet. . . . . 193

    Caloric Restriction . . . . . 193

    No Processed, Refined, Low-Nutrient Foods . . . . . 194

    Minimal Animal-Based Foods . . . . . 194

    Moderate Raw Unprocessed Fats . . . . . 194

    Generous Phytonutrient-Rich Plants. . . . . 195

    Other Nutritional Products. . . . . 197

    Hormone Optimization. . . . . 199

    Avoidance Considerations . . . . . 199

    Detoxification Considerations . . . . . 201

    Reckeweg Phases . . . . . 201

    Bioenergetics and Psychosomatic Energy. . . . . 203

    Structural Considerations . . . . . 203

Discussion of Westergren Sedimentation Rate . . . . . 204

Fibrinogen . . . . . 205

Clinical insights into understanding increased plasma fibrinogen . . . . . 206

Clinical considerations for managing elevated fibrinogen 207

    Nutritional Considerations . . . . . 207

    Inhibit Platelet Aggregation . . . . . 207

    Reduce Inflammation . . . . . 207

    Increase Fibrinogen Degradation. . . . . 207

    Avoidance Considerations . . . . . 209

    Miscellaneous . . . . . 209

Clinical insights into understanding decreased plasma fibrinogen . . . . . 210

Mean Platelet Volume (MPV) . . . . . 210

Other Markers of Inflammation . . . . . 211

    Ferritin . . . . . 211

    Globulins . . . . . 211

    Platelet Count . . . . . 211

Chapter 5 Summary . . . . . 212

**Chapter 6: Hepatobiliary Activity Enzymes. . . 213**

Discussion of Alkaline Phosphatase (AP) . . . . . 214

    Activators and Inhibitors. . . . . 215

    Hepatobiliary Alkaline Phosphatase . . . . . 216

    Osteoblastic Alkaline Phosphatase . . . . . 217

Clinical insights into understanding increased serum alkaline phosphatase . . . . . 217

Clinical considerations for managing increased alkaline phosphatase. . . . . 221

    Filtration . . . . . 221

    Biliary Secretion . . . . . 221

    Enzymatic Transformation . . . . . 221

    Nutritional Considerations . . . . . 221

    Avoidance Considerations . . . . . 222

    Glutathione . . . . . 224

    Phase I and Phase II Balance . . . . . 225

    Phase II Detoxification . . . . . 225

    Glutathione Conjugation. . . . . 225

    Amino Acid Conjugation . . . . . 228

    Methylation. . . . . 228

    Sulfation. . . . . 228

    Acetylation . . . . . 229

    Glucuronidation . . . . . 229

    Sulfoxidation . . . . . 229

    Phase 0 and III Detoxification . . . . . 230

Clinical insights into understanding decreased serum alkaline phosphatase . . . . . 230

Clinical considerations for managing decreased alkaline phosphatase. . . . . 232

Discussion of Aspartate Transaminase (SGOT-AST) . . . . . 232

    Aspartate Transaminase (AST). . . . . 232

Clinical insights into understanding increased serum AST. . . . . 232

Discussion of Alanine Transaminase (SGPT-ALT).....	233
<b>Clinical insights into understanding increased serum</b>	
<b>ALT</b> .....	234
Nonalcoholic Fatty Liver Disease.....	234
Viral Hepatitis.....	235
AutoImmune Hepatitis.....	235
Primary Biliary Cirrhosis (PBC).....	235
Toxin-Related Hepatitis.....	235
<b>Clinical insights into understanding decreased serum</b>	
<b>AST and ALT</b> .....	237
<b>Brief Discussion of Gamma Glutamyl Transferase (GGT)</b>	238
GGT Is a Sensitive Marker of Hepatobiliary Stress.....	238
GGT Elevations in Other Conditions.....	238
GGT Associations with Cancer.....	238
GGT Is a Marker of Oxidative Stress.....	239
GGT Association with Toxic Burden.....	239
Decreased GGT.....	239
<b>Clinical considerations for managing elevated</b>	
<b>hepatobiliary activity enzymes</b> .....	240
Symptoms Related to the Liver.....	240
Traditional Chinese Medicine.....	240
Hepatobiliary Visceroneural Connections.....	241
Avoid Overloading the Liver.....	242
Addressing an Above Ideal GGT Level.....	243
Silybum Marianum (Milk Thistle).....	243
Picrorhiza Kurroa.....	244
Curcuma Longa (Turmeric).....	244
Glycyrrhiza Glabra (Licorice).....	245
Camellia Sinensis (Green Tea).....	245
Phosphatidylcholines.....	246
<b>Brief Discussion of Lactate Dehydrogenase (LDH)</b> .....	247
Serum LDH.....	249
<b>Brief Discussion of Bilirubin</b> .....	250
Total Bilirubin.....	250
Indirect Serum Bilirubin.....	250
Direct Serum Bilirubin.....	251
Low Serum Bilirubin.....	251
<b>Chapter 6 Summary</b> .....	252
<b>Chapter 7: Electrolytes</b> .....	253
Maintenance of Membrane Potential.....	253
Nutrient Absorption and Transport.....	253
<b>Discussion of Serum Sodium</b> .....	253
Renin-Angiotensin-Aldosterone System.....	254
Anti-Diuretic Hormone (ADH).....	254
Natriuretic Peptides.....	254
<b>Clinical insights into understanding increased sodium</b>	
<b>concentration</b> .....	256
<b>Clinical considerations for managing elevated sodium</b>	
<b>concentration</b> .....	257
<b>Clinical insights into understanding decreased sodium</b>	
<b>concentration</b> .....	257
<b>Clinical considerations for managing decreased sodium</b>	
<b>concentration</b> .....	259
Hypovolemic Hyponatremia.....	259
Euvolemic Hyponatremia.....	259
Hypovolemic Hyponatremia.....	260
<b>Clinical Adrenal Inadequacy</b> .....	261
Primary Adrenal Insufficiency.....	261
Secondary Adrenocorticoid Insufficiency.....	261
Tertiary Adrenocorticoid Insufficiency.....	261
Pregnenolone.....	262
Glucocorticoids.....	262
AdrenoCorticoTrophic Hormone (ACTH).....	264
Adrenal Androgens.....	264
Mineralocorticoids.....	265
<b>Clinical manifestations of clinical adrenal inadequacy</b>	
<b>(CAI)</b> .....	265
Laboratory Findings in CAI.....	268
<b>Clinical considerations for managing clinical adrenal</b>	
<b>inadequacy (CAI)</b> .....	269
Nutritional Considerations for CAI.....	269
Adrenal Steroid Replacement.....	271
Dehydroepiandrosterone (DHEA).....	272
Avoidance Considerations for CAI.....	273
Detoxification Considerations for CAI.....	273
<b>Discussion of Serum Potassium</b> .....	273
Hormonal Influences on Serum Potassium.....	274
Water and sodium influence on serum potassium.....	275
<b>Clinical insights into understanding increased serum</b>	
<b>potassium</b> .....	277
Hypoadosteronism.....	277
<b>Clinical considerations for managing increased serum</b>	
<b>potassium</b> .....	277
<b>Clinical insights into understanding decreased serum</b>	
<b>potassium</b> .....	278
Rheumatoid Arthritis.....	279
<b>Clinical considerations for managing decreased serum</b>	
<b>potassium</b> .....	279
Chronic Adrenal Hyperfunction.....	279
Nutritional Considerations.....	281
Reducing Elevated Cortisol.....	281
Reducing Upregulated 11 $\beta$ -HSD1.....	282
Avoidance Considerations.....	283
<b>Discussion of Serum Chloride</b> .....	283
<b>Clinical insights into understanding increased serum</b>	
<b>chloride</b> .....	283
<b>Clinical considerations for managing increased serum</b>	
<b>chloride</b> .....	284
<b>Clinical insights into understanding decreased serum</b>	
<b>chloride</b> .....	284
<b>Clinical considerations for managing decreased serum</b>	
<b>chloride</b> .....	285
<b>Discussion of Serum Bicarbonate</b> .....	285

**Clinical insights into understanding elevated serum bicarbonate** . . . . . 286

- Loss of Hydrogen Ions . . . . . 286
- Excessive Intake of Alkalizers . . . . . 286
- Shift of Hydrogen Ions . . . . . 286

**Clinical insights into understanding low serum bicarbonate** . . . . . 286

**Discussion of the Anion Gap** . . . . . 287

- Bicarbonate and the “Corrected Bicarbonate” . . . . . 288
- Normal Anion Gap Acidosis (12-16). . . . . 289
- High Anion Gap Acidosis (>14-18). . . . . 289
- Low Anion Gap (<8) . . . . . 291

**Chapter 7 Summary** . . . . . 292

**Chapter 8: Red Blood Cells and Platelets** . . . . . 293

**Discussion of Red Blood Cell (Erythrocyte) Count** . . . . . 293

**Clinical insights into understanding increased RBC count** 294

- Hypoxia Driven . . . . . 294
- Non-Hypoxia Driven . . . . . 294

**Clinical considerations for managing increased RBC count** . . . . . 294

**Clinical insights into understanding decreased RBC count** . . . . . 295

- Insufficient Reticulocyte Production . . . . . 295
- Excessive Red Cell Destruction . . . . . 296
- Blood Loss . . . . . 296

**Clinical considerations for managing decreased RBC count** . . . . . 297

**Discussion of Hemoglobin (Hgb)** . . . . . 297

**Clinical insights into understanding elevated hemoglobin** 297

- Hypoxia Driven . . . . . 298
- Non-Hypoxia-Driven . . . . . 298

**Clinical insights into understanding low hemoglobin** . . . . . 298

- Insufficient Hemoglobin Production . . . . . 298
- Loss of Hemoglobin . . . . . 298
- Genetic Defects in Hemoglobin Products . . . . . 299

**Discussion of Hematocrit (HCT)**. . . . . 299

**Clinical insights into understanding elevated hematocrit** . 299

**Clinical insights into understanding decreased hematocrit** . . . . . 299

**Discussion of Mean Corpuscular Volume (MCV) and Hemoglobin (MCH)** . . . . . 301

**Clinical insights into understanding macrocytosis (elevated MCV)** . . . . . 301

- Megaloblastic Macrocytosis . . . . . 301
- Vitamin B<sub>12</sub> Insufficiency . . . . . 302
- Folate Deficiency . . . . . 303
- Non-Megaloblastic Macrocytosis . . . . . 305
- Clinical Thyroid Inadequacy . . . . . 305

**Clinical considerations for managing macrocytosis (elevated MCV)** . . . . . 307

- Cobalamins . . . . . 307
- Folates . . . . . 309
- Folate Sources and Supplementation . . . . . 310
- Folate Measurements . . . . . 310
- Folate Metabolism . . . . . 311
- Methylation . . . . . 312
- S-Adenosylmethionine (SAME) . . . . . 313
- Methionine Synthase . . . . . 314
- Betaine Homocysteine Methyl Transferase (BHMT) . . . . . 315
- S-Adenosylhomocysteine (SAH) . . . . . 316
- Homocysteine . . . . . 316
- Cystathionine β Synthase (CBS) . . . . . 318
- Carnitine . . . . . 320
- Clinical Thyroid Inadequacy . . . . . 320
- Cellular Uptake of T<sub>4</sub> and T<sub>3</sub> . . . . . 320
- Deiodination . . . . . 321
- Thyroid Stimulating Hormone (TSH) . . . . . 323
- Iodine Inadequacy . . . . . 324
- Iodine Excess . . . . . 324

**Clinical insights into understanding microcytosis (decreased MCV)** . . . . . 325

- Thalassemias . . . . . 325
- Sideroblasts . . . . . 326

**Clinical considerations for managing microcytosis (low MCV)** . . . . . 326

- Parasitosis and Parasites . . . . . 329

**Discussion of Red Cell Random Distribution of Width (RDW)** . . . . . 330

**Clinical insights into understanding elevated RDW** . . . . . 330

**Clinical insights into understanding decreased RDW** . . . . . 331

**Brief Discussion of the Platelet Count** . . . . . 331

**Clinical insights into understanding an increased platelet count** . . . . . 332

**Clinical considerations for managing an increased platelet count** . . . . . 332

- Inhibition of Platelet Aggregation/Adhesion/Activation 333

**Clinical insights into understanding a decreased platelet count** . . . . . 334

**Clinical considerations for managing a decreased platelet count** . . . . . 334

- Nutritional Considerations . . . . . 334
- Avoidance Considerations . . . . . 335

**Chapter 8 Summary** . . . . . 336

**Chapter 9: Serum Lipids** . . . . . 337

**Cholesterol** . . . . . 337

- As a Constituent of Cell Membranes . . . . . 337
- Cholesterol Oxidation . . . . . 338
- Other Functions of Cholesterol . . . . . 339
- Cholesterol Esters . . . . . 339

**Clinical insights into understanding elevated total cholesterol** . . . . . 339

<b>Clinical considerations for managing elevated total cholesterol</b> . . . . .	341
Nutritional Considerations . . . . .	341
Soluble Dietary Fibers . . . . .	341
Replacing Animal Proteins . . . . .	341
Plant Sterols and Stanols . . . . .	342
Garlic . . . . .	342
Almonds and Nuts . . . . .	343
Green Tea . . . . .	343
Chitosan . . . . .	343
Avoidance Considerations . . . . .	343
<b>Clinical insights into understanding low total cholesterol</b> . . . . .	343
Cholesterol Reduction . . . . .	344
Low Cholesterol and Low Albumin . . . . .	344
<b>Clinical considerations for managing low total cholesterol</b> . . . . .	345
<b>Lipoproteins</b> . . . . .	345
High Density Lipoproteins (HDLs) . . . . .	346
HDLs Are Atheroprotective . . . . .	346
HDLs and Immunity . . . . .	346
HDLs and Steroidogenesis . . . . .	346
Low Density Lipoproteins (LDLs) . . . . .	347
LDL Modification (Oxidation and Glycation) . . . . .	347
LDLs and Immunity . . . . .	347
<b>Clinical insights into lipoprotein levels</b> . . . . .	348
<b>Clinical considerations for optimizing lipoprotein levels</b> . . . . .	348
Dietary Fat Intake . . . . .	348
Other Considerations to Raise HDLs . . . . .	349
Nicotinic Acid (Niacin) . . . . .	349
Pantethine (Vitamin B <sub>5</sub> ) . . . . .	352
Thyroxine Replacement . . . . .	352
HMG CoA Reductase Inhibitors (Statins) . . . . .	352
Berberine . . . . .	353
<b>Triglycerides (TGs)</b> . . . . .	353
<b>Clinical insights into understanding elevated serum triglycerides</b> . . . . .	354
<b>Clinical considerations for managing elevated serum triglycerides</b> . . . . .	354
<b>Clinical insights into understanding low serum triglycerides</b> . . . . .	355
<b>Clinical considerations for managing low serum triglycerides</b> . . . . .	356
<b>Atherogenic Dyslipidemia</b> . . . . .	356
Predicting Cardiovascular Disease . . . . .	357
Coronary Artery Calcium (CAC) Score . . . . .	357
<b>Clinical considerations for managing atherogenic dyslipidemia</b> . . . . .	358
Optimizing Endothelial Function and Vascular Integrity (1) . . . . .	358
Reduce LDL (2) . . . . .	359
Plant Sterols . . . . .	359
Beta-Glucans . . . . .	359
Psyllium Husks . . . . .	359
Red Yeast Rice (RYR) . . . . .	360
Avoid Nighttime Snacking . . . . .	360
Inhibit LDL Modification (3) . . . . .	360
Vegetables and Fruits . . . . .	361
Taurine . . . . .	361
Spirulina . . . . .	361
Phenolic Antioxidants . . . . .	361
Other Antioxidants . . . . .	361
Amla . . . . .	362
Reduce Glycation . . . . .	362
Reduce AGEs Intake . . . . .	364
Reduce Insulin . . . . .	365
Statins . . . . .	365
Inhibit Subendothelial Uptake (4) . . . . .	366
Address elevated Lp(a) . . . . .	366
Reducing Lipoprotein-Associated Phospholipase A <sub>2</sub> (Lp-PLA <sub>2</sub> ) . . . . .	367
Repair Atherosclerotic Plaque (5) . . . . .	368
Increased HDL . . . . .	369
Phosphatidylcholine . . . . .	369
Sodium Thiosulfate . . . . .	369
Dietary Fat Intake . . . . .	369
Statins . . . . .	370
Berberine . . . . .	370
Bioenhancers Are Critical to Clinical Efficacy . . . . .	370
P-Glycoprotein (P-gp) . . . . .	370
Preconditioning (6) . . . . .	372
Multifactorial Considerations . . . . .	373
Testosterone . . . . .	373
Estrogen . . . . .	374
Melatonin . . . . .	374
Adrenal Hormones . . . . .	374
Growth Hormone and IGF-1 . . . . .	375
Thyroid . . . . .	375
<b>Selected Topics Regarding Dietary Lipids</b> . . . . .	376
Healthy Dietary Fats/Oils . . . . .	376
Saturated Fats . . . . .	377
Essential Fats . . . . .	377
Tree-Nut Consumption . . . . .	377
Trans-Fatty Acids . . . . .	378
Conjugated Linoleic Acids (CLAs) . . . . .	379
Omega-6 PUFAs . . . . .	380
Omega-3 Versus Omega-6 . . . . .	382
Omega-3 PUFAs (EPA and DHA) . . . . .	382
<b>Chapter 9 Summary</b> . . . . .	384
<b>Appendix I: Mechanisms of Disease</b> . . . . .	385
Management Fundamentals . . . . .	385
Avoidance . . . . .	385
Detoxification . . . . .	386
Nourishment . . . . .	387
Maladaptive Emotional Behaviors . . . . .	388
Interference Fields . . . . .	389
<b>Appendix II: Dr. Page's Calcium/Phosphorus Ratio &amp; The Endocrine Graph</b> . . . . .	393

**Appendix III: The Page Fundamental Food Plan . . . . . 399**

- Foods to Eat and Not Eat. . . . . 399
- Eat Smaller Amounts More Frequently. . . . . 402
- Supplementation. . . . . 402
- The Influence of Blood Type. . . . . 403

**Appendix IV: Food Combining . . . . . 407**

- Understanding Food Combining. . . . . 407
- Two types of digestion – acid and alkaline. . . . . 408
- RULE 1: Don't combine pure fats with high starch foods. . 408
- RULE 2: Don't combine acids with carbohydrates. . . . . 409
- RULE 3: Do not combine proteins with starches. . . . . 409
- Caloric Restriction and the Page Food Plan. . . . . 411

**Appendix V: Blood Chemistry Markers & Common Clinical Patterns. . . . . 415**

- Common health conditions, their tendencies on lab results, and chapter location to find more information . . . 416

**Index . . . . . 419**



## List of Tables

Vitamin B Complex . . . . .	11	Effects of One Week of Feeding Diets High in Carbohydrate, Saturated Fat or Polyunsaturated Fats On Neuronal (C-Fos) Activation . . . . .	124
Vitamin B Fraction. . . . .	11	Products of White Adipose Tissue (WAT) . . . . .	132
Vitamin G Fraction . . . . .	11	Influences on Serum Leptin Levels . . . . .	133
Chemical Characteristics . . . . .	11	Roles of Human Serum Albumin. . . . .	148
Sources. . . . .	11	Mechanisms of Elevated Albumin. . . . .	148
Components . . . . .	11	GI Effects of Autonomic Nervous System. . . . .	156
Deficiency Associations/Effects . . . . .	11	Causes of Enhanced Intestinal Permeability . . . . .	160
Manifestations of Hypercalcemia. . . . .	12	Globulins . . . . .	163
Root Causes. . . . .	16	Elevated Globulins . . . . .	164
Management Approach. . . . .	16	Pathway to Inflammation . . . . .	181
↑ Serum Calcium with ↑ Tissue Calcium. . . . .	16	Changes in Concentrations of Plasma Proteins in the Acute-Phase Response. . . . .	183
↑ Serum Calcium with Possible ↓ Tissue Calcium . . . . .	17	Summary of the Low-Inflammation Food Plan. . . . .	196
Urinary Calcium Excretion. . . . .	17	Paths Marine n-3 PUFAs Use to ↓ Inflammation . . . . .	199
Selected Causes of Elevated Serum Calcium with a Low serum PTH . . . . .	18	In the Body, Everything Functions in Balance. Balance Between Dualism. . . . .	200
Low Total Serum Calcium . . . . .	21	ESR Reference Ranges in Healthy Adults . . . . .	204
Consequences of Vitamin F Deficiency . . . . .	22	Factors Influencing Sedimentation Rates . . . . .	204
Clinical Features Associated With Hypocalcemia. . . . .	22	Elevated Alkaline Phosphatase (AP-1) . . . . .	218
Upper Tolerable Limit of Daily Calcium Intake. . . . .	30	Elevated Alkaline Phosphatase (AP-2) . . . . .	219
Elevated Phosphorus . . . . .	38	Elevated Alkaline Phosphatase in Non-Bone/Non-Liver Conditions. . . . .	220
Hypophosphatemia and Phosphate Insufficiency . . . . .	41	Select Inducible Cytochrome P450 Enzymes. . . . .	223
Micro-Endocrine Considerations . . . . .	44	Substances That Activate Phase I Detoxification (in general) . . . . .	225
Conditions to Consider Related to Vit D3 Need* . . . . .	51	Inhibitors of Phase I Detoxification (in general) . . . . .	225
Vitamin D <sub>3</sub> Levels to Prevent Disease. . . . .	52	The Major Regulators of Cellular Redox. . . . .	226
1980's USDA Databases List the Vitamin D Content per 100 grams (~3 ½ Ounces) — IUs. . . . .	55	γ Glutamylcysteine Synthetase Activity or Transcription. . . . .	227
Does a Low Vitamin D <sub>3</sub> Level Always Warrant Oral Vitamin D <sub>3</sub> Supplementation? . . . . .	56	Roles of Glutathione . . . . .	228
Possible Influence of Medications . . . . .	59	Conditions Associated with Low Serum Alkaline Phosphatase (AP). . . . .	231
Typical Biochemical Features of Hyperparathyroidism . . . . .	61	Aspartate Transaminase (AST). . . . .	232
Nutrients* to Enable Bone Mineralization . . . . .	62	Alanine Transaminase (ALT) . . . . .	233
Symptoms Suggestive of Magnesium Need . . . . .	68	Hepatocellular Conditions (AST and ALT elevations predominate) . . . . .	234
Conditions associated with Dysaerobic Metabolism . . . . .	81	Cholestatic Conditions (AP and GGTP elevations predominate) . . . . .	234
Conditions associated with Anaerobic Metabolism . . . . .	81	Medications that influence on the liver. . . . .	236
Anti-Dysaerobic→ More Anaerobic. . . . .	87	Conditions Associated with ↑ ALT . . . . .	237
Anti-Anaerobic → More Dysaerobic . . . . .	87	Group Five from the Symptom Survey . . . . .	240
NeuroEndocrine Bio-Energy Regulators . . . . .	91	Herbal Inhibitors of Cytochrome P450 Enzymes . . . . .	242
Metabolic Actions of Insulin and Glucagon. . . . .	93	Possible Herbal Influences on Glucuronidation . . . . .	243
Factors Affecting GH Release. . . . .	94	Contributors to Increased Lactate Production. . . . .	248
Conversion of HgbA1c to Average Glucose Level. . . . .	100	Increased Total Bilirubin. . . . .	250
KRAFT Glucose-Insulin Tolerance Curve Patterns . . . . .	100	Hypernatremia . . . . .	257
HOMA-Insulin Resistance . . . . .	103	Hyponatremia . . . . .	258
Vitamin B Fraction. . . . .	108	Herbs with Diuretic Action. . . . .	259
R-Lipoic Acid for Glucose Regulation. . . . .	115	Classical Adrenal Insufficiency . . . . .	261
IR & Obese/Overweight Individual. . . . .	116		
IR & Normal-Weight Individual . . . . .	116		
Hyperglycemia Without IR. . . . .	116		

Laboratory Findings (Relative) Suggestive of Hypoadrenia.	268
The Ideal Anion Gap (mEq/L) . . . . .	288
Causes of Normal Anion Gap Acidosis (12-16). . . . .	289
Causes of an Elevated Serum Anion Gap (>18). . . . .	290
Causes of a Low Serum Anion Gap (<8). . . . .	291
Low Hemoglobin/Hematocrit with Low WBC Count or Platelets . . . . .	300
Causes of Megaloblastic Macrocytosis . . . . .	304
Pathways of Thyroxine Metabolism. . . . .	305
Causes of Non-Megaloblastic Macrocytosis. . . . .	307
False Causes of Elevated Serum Homocysteine and Methylmalonic Acid Levels. . . . .	309
Nutrients that Promote Methylation. . . . .	319
Influences on Deiodination (T <sub>3</sub> vs. r T <sub>3</sub> ). . . . .	322
Predominant Effects on TSH Secretion in Humans . . . . .	323
Iodine. . . . .	324
Common Diagnoses of Microcytosis . . . . .	325
Suggested Diagnoses with Low MCV . . . . .	326
Factors Influencing Iron Absorption. . . . .	327
Soluble Transferrin Receptor (sTfR) >5mg/L. . . . .	328
Conditions That May Involve Parasites. . . . .	329
Increased Platelets (>300,000 per cu mm) . . . . .	332
Platelet Inhibition. . . . .	333
Decreased (< 150,000 per cu mm). . . . .	334
Phase Angle. . . . .	338
Reducing Elevated Triglycerides . . . . .	355
AGE Content (Units) . . . . .	364
Effect of CLA Supplementation . . . . .	380
Omega-6 PUFA Sources . . . . .	381
Arachidonic Acid (mg/100grams) and Error Ranges . . . . .	382
Known Observations of EPA + DHA Compared With Isolated EPA or DHA. . . . .	383

## List of Text Boxes

The hormones most influential on serum IONIZED calcium levels . . . . .	2	Revisiting Na <sup>+</sup> /K <sup>+</sup> ATPase. . . . .	263
High Calcium/Low Oxalate Vegetables. . . . .	5	Dr. Melvin Page's Anthropometrics. . . . .	265
Symptoms and Signs of Biliary Insufficiency . . . . .	24	Hyperemesis Gravida — Hypoadrenia? . . . . .	267
COW'S MILK. . . . .	27	The Sodium-Potassium Pump . . . . .	274
MILK PROCESSING. . . . .	29	Serum Potassium Is a Reflection . . . . .	274
Vitamin D Receptor (VDR) . . . . .	46	Lactate and Bicarbonate Levels . . . . .	287
EMANUEL REVICI, MD . . . . .	74	Determining Iodide Sufficiency. . . . .	305
Sialic Acid . . . . .	76	Iodide Accumulation Into the Thyroid . . . . .	305
Carbohydrates and SNS Activity . . . . .	94	Folinic Acid vs 5-MTHF Supplementation. . . . .	310
Medications That Increase Insulin. . . . .	98	Features of Over-methylation. . . . .	313
Free Fatty Acids . . . . .	102	Features of Under-methylation . . . . .	313
NAFLD . . . . .	105	Betaine. . . . .	315
Premature Dementia — Type 3 Diabetes? . . . . .	106	Our Vulnerable Mitochondria . . . . .	320
Sleep Disorders and Daytime Fatigue due to Insulin? . . . . .	111	Conditions that decrease Cellular T <sub>4</sub> and T <sub>3</sub> Uptake . . . . .	321
Mechanisms Increasing Blood Glucose . . . . .	111	Lipoprotein Terminology . . . . .	345
Mechanisms Decreasing Blood Glucose. . . . .	111	Brain-Derived Neurotrophic Factor (BDNF). . . . .	350
AMP-Activated Protein Kinase (AMPK) . . . . .	112	Pellagra. . . . .	350
Mitochondrial Diversity . . . . .	113	Why Is Fructose More Problematic Than Glucose? . . . . .	363
Thyroid Increases Mitochondrial Activity . . . . .	113	Arabinose . . . . .	364
Metformin. . . . .	121	P-Glycoprotein — Multi Drug Resistance . . . . .	370
Caloric Restriction. . . . .	125	Bioenhancers: Improving Clinical Efficacy. . . . .	372
Food Choices to Reduce Inflammation. . . . .	127	Testosterone Counterbalances Adrenal Excess . . . . .	375
Reversing Type 2 Diabetes (T2D) . . . . .	129		
Obesity — Adiposity . . . . .	135		
Observations About Water . . . . .	150		
Pre-Eclampsia Prevention. . . . .	151		
ZINC . . . . .	152		
Insulin-Like Growth Factor-1 (IGF-1) . . . . .	154		
Impaired Digestion . . . . .	159		
Anti-Diuretic Hormone . . . . .	169		
Cranial Osteopathy . . . . .	170		
Inosine . . . . .	175		
Hyperuricemia does not equal Gout. . . . .	176		
Molybdenum. . . . .	178		
Summary of CRP Functions . . . . .	186		
Associations with Elevated C-Reactive Protein . . . . .	187		
Olive Oil. . . . .	198		
Periodontal Disease . . . . .	203		
Interleukin-6 (and Adiposity/Stress). . . . .	209		
Alkaline Phosphatase — a Role in Cancer? . . . . .	215		
Supplements to Increase Glutathione . . . . .	227		
Copper Imbalances — Dr. Paul Eck . . . . .	236		
Piperine . . . . .	245		
The NAD <sup>+</sup> / NADH Ratio (The Redox State of the Cell) . . . . .	247		
Elevated Serum LDH . . . . .	249		
Decreased Total Bilirubin . . . . .	251		
Body Impedance Analysis. . . . .	255		
Sodium Chloride — Salt . . . . .	260		